PRESS RELEASE published on 07/25/2025 at 07:30, 1 year 3 months ago Inside Information / Other news releases Advicenne reports H1 2025 sales of €2.6 million, with direct sales rising 17% and Sibnayal® sales in Europe up 90% compared to H1 2024. Company's cash flow horizon extends to Q3 2026 Cash Flow Pharmaceutical Advicenne Sibnayal H1 2025 Sales
BRIEF published on 07/21/2025 at 20:57, 1 year 3 months ago Advicenne raises 2.6 million euros to strengthen its financial capacity Capital Increase Financial Market Bpifrance Kidney Diseases Advicenna
BRIEF published on 03/27/2025 at 19:17, 1 year 7 months ago Advicenne Reports Solid Growth and Future Plans for 2025 Cash Flow Improvement 2025 Outlook Advicenne Financial Results Sibnayal Sales Growth ADV7103 Regulatory Progress
PRESS RELEASE published on 03/27/2025 at 19:12, 1 year 7 months ago Inside Information / News release on accounts, results Advicenne reports successful commercial performance of Sibnayal® in Europe, with total product sales up 9.4% to €4.9m. Major strides in US development with NDA filing expected in Q3 2025 Financial Results Advicenne Commercial Performance Sibnayal US Development
BRIEF published on 10/01/2024 at 07:05, 2 years 1 month ago Advicenne Advances in US with Positive FDA Reviews for ADV7103 FDA ADV7103 ATRd Advicenna Cystinuria
PRESS RELEASE published on 10/01/2024 at 07:00, 2 years 1 month ago Inside Information / Other news releases Advicenne achieves major milestones in the US with positive FDA opinions on ADV7103, accelerating partnership outlook for commercialization, preparing for clinical development in cystinuria, and seeking commercial partners Commercialization Advicenne ADV7103 Cystinuria FDA Opinions
BRIEF published on 05/15/2024 at 09:07, 2 years 5 months ago Advicenne Shareholders Approve Board-Supported Resolutions at General Meeting Euronext Growth Paris Pharmaceutical Industry General Meeting Advicenne Rare Renal Diseases
PRESS RELEASE published on 05/15/2024 at 09:02, 2 years 5 months ago Inside Information / Other news releases Advicenne's Board of Directors' resolutions approved at the Combined General Meeting. Shareholders support all resolutions including financial statements and delegations Board Of Directors Shareholders Financial Statements Combined General Meeting Advicenne
BRIEF published on 05/15/2024 at 08:06, 2 years 5 months ago Advicenne launches a share buyback program Share Buyback Euronext Growth Financial Market Advicenne Kidney Diseases
Published on 11/06/2026 at 13:00, 1 hour 56 minutes ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 hours 26 minutes ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 hours 26 minutes ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 05:15, 9 hours 41 minutes ago Valeo and QNX Unveil A New Smart Camera Platform at CIIE, Secures Multiple Design Wins
Published on 11/06/2026 at 14:45, 11 minutes ago Ningbo Consensus on Collaborative Development released at 2026 Global Mayors Dialogue · Ningbo
Published on 11/06/2026 at 14:40, 16 minutes ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 11/06/2026 at 14:39, 16 minutes ago Form 8.3 - The Vanguard Group, Inc.: Permanent TSB Group Holdings plc
Published on 11/05/2026 at 18:21, 20 hours 34 minutes ago Total number of voting rights and shares making up the share capital at October 31, 2026
Published on 11/05/2026 at 17:45, 21 hours 11 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 11/05/2026 at 17:29, 21 hours 26 minutes ago Notice of exercise of early redemption option of the subordinated note ISIN FR0010406082
